{"doi":"10.1016/j.blre.2020.100714","title":"Current management strategies for polycythemia vera and essential thrombocythemia","abstract":null,"journal":"Blood Reviews","year":2020,"id":633647,"datarank":0.6166310796259968,"base_score":4.110873864173311,"endowment":4.110873864173311,"self_citation_contribution":0.6166310796259968,"citation_network_contribution":0.0,"self_endowment_contribution":0.6166310796259968,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":60,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":628534,"name":"Alessandro M. Vannucchi","orcid":"0000-0001-5755-0730","position":1,"is_corresponding":false},{"id":851194,"name":"Paola Guglielmelli","orcid":"0000-0003-1809-284X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Current management strategies for polycythemia vera and essential thrombocythemia","abstract":"Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of cardiovascular events, a varying burden of symptoms, and an intrinsic risk of evolution to secondary forms of myelofibrosis and acute leukemia; however, survival is only modestly reduced in most instances. In the last few years, following the description of driver mutations in JAK2, MPL and CALR, the diagnostic criteria for PV and ET were revised, making the identification of very early stages feasible. Scores for identifying patients at different risk of thrombosis were refined, and they largely guide therapeutic decisions. Treatment is therefore mainly focused on reduction of thrombosis risk, control of myeloproliferation, improvement of symptomatic burden, and management of disease-associated complications. New drugs recently entered the clinical arena, with the promise to improve overall patients' management. However, evidence of a disease-modifying potential is largely missing and represents a still unmet clinical need.","is_dataset_classified":null,"base_score":4.110873864173311,"endowment":4.110873864173311,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"32546373","pmcid":null,"openalex_id":"https://openalex.org/W3032977845","authors":[],"funders":[],"total_grants":0,"fwci":3.9345,"citation_percentile":0.94713827,"influential_citations":0,"citation_trend":[{"year":2020,"count":4},{"year":2021,"count":4},{"year":2022,"count":12},{"year":2023,"count":15},{"year":2024,"count":15},{"year":2025,"count":5},{"year":2026,"count":5}],"oa_status":"bronze","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://www.sciencedirect.com/science/article/pii/S0268960X20300643","host_type":"journal"},{"url":"https://www.sciencedirect.com/science/article/pii/S0268960X20300643","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0268960X20300643?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0268960X20300643?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.blre.2020.100714","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/32546373","host_type":"repository"},{"url":"http://hdl.handle.net/2158/1260675","host_type":"repository"}],"fields_of_study":["Myeloproliferative Neoplasms: Diagnosis and Treatment","Kruppel-like factors research","Acute Myeloid Leukemia Research","Animals","Disease Management","Humans","Polycythemia Vera","Thrombocythemia, Essential","Thrombosis"],"mesh_terms":["Animals","Humans","Polycythemia Vera","Thrombocythemia, Essential","Thrombosis","Disease Management"],"keywords":["Essential thrombocythemia","Polycythemia vera","Myelofibrosis","Medicine","Intensive care medicine","Myeloproliferative neoplasm","Disease","Myeloproliferative Disorders","Thrombosis","Acute leukemia","Ruxolitinib","Internal medicine","Leukemia","Bone marrow","Hydroxyurea","JAK2"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T12:25:43.568989Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}